| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU ; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 16 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population | Yu M.-L.; PEI-JER CHEN ; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 16 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L. | Journal of the Formosan Medical Association | 16 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU ; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 21 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | Yu M.-L.; PEI-JER CHEN ; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 21 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L. | Journal of the Formosan Medical Association | 21 | ||
| 2015 | Amiodarone as an autophagy promoter reduces liver injury and enhances liver regeneration and survival in mice after partial hepatectomy | Lin C.-W.; Chen Y.-S.; Lin C.-C.; Chen Y.-J.; Lo G.-H.; PO-HUANG LEE ; Kuo P.-L.; Dai C.-Y.; Huang J.-F.; Chung W.-L.; Yu M.-L. | Scientific Reports | 37 | ||
| 2019 | APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? | Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Sarin S.K.; Omata M. | Hepatology International | 18 | ||
| 2012 | APASL consensus statements and management algorithms for hepatitis C virus infection | Omata M.; Kanda T.; Yu M.-L.; Yokosuka O.; Lim S.-G.; Jafri W.; Tateishi R.; Hamid S.S.; Chuang W.-L.; Chutaputti A.; Wei L.; Sollano J.; Sarin S.K.; JIA-HORNG KAO ; McCaughan G.W. | Hepatology International | 130 | ||
| 2016 | APASL consensus statements and recommendation on treatment of hepatitis C | Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Lau G.K.K.; Sarin S.K. | Hepatology International | 136 | ||
| 2016 | APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing | Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Al-Mahtab M.; McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Lau G.K.K.; Sarin S.K. | Hepatology International | 56 | ||
| 2019 | APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation | Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Kadir Dokmeci A.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Ooka Y.; Yokosuka O.; Sarin S.K.; Omata M. | Hepatology International | 22 | ||
| 2017 | The autophagy marker LC3 strongly predicts immediate mortality after surgical resection for hepatocellular carcinoma | Lin C.-W.; Lin C.-C.; PO-HUANG LEE ; Lo G.-H.; Hsieh P.-M.; Koh K.W.; Lee C.-Y.; Chen Y.-L.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Chen Y.-S.; Yu M.-L. | Oncotarget | 9 | ||
| 2018 | Autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection article | Lin C.-W.; Chen Y.-S.; Lin C.-C.; PO-HUANG LEE ; Lo G.-H.; Hsu C.-C.; Hsieh P.-M.; Koh K.W.; Chou T.-C.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Chen Y.-L.; Yu M.-L. | Clinical and Translational Gastroenterology | 10 | ||
| 2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; TUNG-HUNG SU ; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. | Liver Cancer | 6 | ||
| 2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; CHEN-HUA LIU ; Chen P.-J.; Chen D.-S.; Kao J.-H. | Liver Cancer | 6 | ||
| 2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; PEI-JER CHEN ; Chen D.-S.; Kao J.-H. | Liver Cancer | 6 | ||
| 2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO | Liver Cancer | 6 | ||
| 2018 | Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan | Hsieh M.-H.; Yeh M.-L.; Su T.-H.; Liu T.-W.; Huang C.-F.; Huang C.-I.; Wang S.-C.; Huang J.-F.; Dai C.-Y.; Kao J.-H.; Chuang W.-L.; PEI-JER CHEN ; Liu C.-J.; Yu M.-L. | Journal of the Formosan Medical Association | 4 | ||
| 2018 | Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan | Hsieh M.-H.; Yeh M.-L.; Su T.-H.; Liu T.-W.; Huang C.-F.; Huang C.-I.; Wang S.-C.; Huang J.-F.; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Chen P.-J.; Liu C.-J.; Yu M.-L. | Journal of the Formosan Medical Association | 4 |
